[Long-term treatment for multiple sclerosis with interferon beta-1b. Outcomes of an open, retrospective, observational study]. / Dolgosrochnaya terapiya rasseyannogo skleroza interferonom beta-1b. Rezul'taty retrospektivnogo otkrytogo nablyudatel'nogo issledovaniya.

OBJECTIVE: To assess the outcomes of long-term treatment in multiple sclerosis (MS) patients with Infibeta (interferon beta-1b). MATERIAL AND METHODS: The article presents the results a real-world, multicenter, retrospective, observational study of treatment with interferon beta-1b. We enrolled 332 patients with MS who had been receiving Infibeta for at least 8 years. 60.2% of them had a relapsing-remitting MS (RRMS). 73.2% patients received only interferon beta-1b that was initial DMT. RESULTS: During the first year of the treatment, 66% of the patients reported no relapses regardless of the MS type. No relapses in the 8th year of treatment were observed in 86.9% of patients with RRMS and 77.7% with secondary progressive MS (SPMS). The median number of relapses during the whole follow-up period in RRMS patients was 1. The time to first relapse in the subgroup of patients who received interferon beta as the first treatment was longer compared to other treatment (median 4 and 2, respectively, p=0.0017). 42% of patients with RRMS remained progression-free during 8 years of follow-up. The flu-like syndrome was observed in 61.7% for the first year of treatment; in 36.3% it was periodically and was mild in 71.3%. CONCLUSION: The study outcomes confirm a high clinical response to the long-term treatment with Infibeta in patients with RRMS and SPMS and demonstrate that interferon beta-1b is one an optimal option for the initial treatment of patients with moderate disease activity.

[Primary progressive multiple sclerosis: current issues of timely diagnosis]. / Pervichno-progressiruiushchii rasseiannyi skleroz: sovremennoe sostoianie problemy svoevremennoi postanovki diagnoza.

This article presents a review of international data on primary progressive multiple sclerosis (PPMS) and an analysis of factors influencing timely diagnosis of PPMS in a number of regions of the Russian Federation.

[An analysis of the epidemiological situation on multiple sclerosis in the Krasnodar region]. / Analiz épidemiologicheskoi situatsii po rasseiannomu sklerozu v Krasnodarskom krae.

The data of a clinical-epidemiological study of multiple sclerosis (MS) in the Krasnodar region are presented. The index of MS prevalence was estimated as 18.95 per 100.000 people. That allows to consider the region as an area with mid-level MS risk. The disease incidence was 2.18 per 100.000 people. The prevalence and incidence were the highest in the Russian population, aged 35-39 years.

[Amino acids content in the blood serum of patients with multiple sclerosis].

Content of amino acids in the blood serum using ion-exchange chromatography and a quantitative crystalloscopic "closed drop" method was measured in 105 patients with multiple sclerosis of different severity. The relation between the dynamics of content of glutamic, asparagine acids and glycine and the disease severity was determined. The highest level of glutamic acid was found in the patients with severe disease course. The dynamics of quantitative changes in the amino acid content was accompanied by the disturbance of blood serum structuration and appearance of selective micromorphotypes. The positive correlation between the severity of motor and coordination disorders and the increase in levels of glutamic acid and glycine in the severe cases was detected.